Abstract-An integrated platform that merges a microfluidic chip with lens-less imaging to target CD4+ T-Iymphocyte counts for point-of-care testing at resource-limited settings. We demonstrate an integrated platform that merges a microfluidic chip with lens-less imaging to target CD4+ T-Iymphocyte counts for point-of-care testing at resource-limited settings. The chips were designed and fabricated simply with a laser cutter instead of using expensive c1eanroom equipment. To capture CD4+ T lymphocytes, anti-CD4 antibody was immobilized on one side of the microfluidic chip. These captured cells were detected through an optically clear chip using a charge coupled device (CCD) sensor by lens-less shadow imaging techniques. Gray scale image of the captured cells in the 24 mm x 4 mm x 50 J1m microfluidic chip was obtained by the platform. The automatic cell counting software enumerated the captured cells in three seconds. Captured cells were also imaged with a fluorescence microscope and manually counted to characterize functionality ofthe integrated platform. We achieved 70.2 ± 6.5% capturing efficiency, 88.8 ± 5.4% capturing specificity for CD4+ T-Iymphocytes, 96 ± 1.6% CCD efficiency, and 83.5 ± 2.4% overall platform performance (n = 9 devices). The integrated platform points a promising direction for point-of-care testing (POCT) to rapidly capture, image and count subpopulations of cells from blood samples in an automated matter.
I. INTRODUCTION The CD4+ T-Iymphocyte count is performed currently 3 ~ 4 times a year in the developed world, and twice a year in the developing world using fluorescent activated cell count and sorting systems (F ACS)I. ART is started for infected persons whose CD4+ T-Iymphocyte count is below 200 ~ 350 cells per microliter 2 • There is a need for rapid diagnostic and monitoring systems that are simple-to-use, inexpensive, reliable, and disposable to complement current monitoring methods.
The chips were designed as shown in fig. 1 and fabricated simply with a laser cutter instead of using expensive cleanroom equipment. To capture CD4+ T lymphocytes, anti-CD4 antibody was immobilized on one side of the microfluidic chip3. These captured cells were detected through an optically clear chip using a charge coupled device (CCD) sensor by lens-less shadow imaging techniques 4 , as shown in fig. 2 .
II. RESULTS Figure 3 shows the microfluidic chip capture specificity, capture efficiency, CCD efficiency, and overall platform performance. The chip specificity and efficiency are related to the surface chemistry and shear based mechanical filtration method. The average value of the three blood samples shows 88.8 ± 5% capture specificity for CD4+ cells and 70.2 ± 6.7% chip capture efficiency (n = 9 devices). Such a rapid CD4 count allows fast feed back at the POC, when compared to existing systems (e.g., magnetic beads: 5 ~ 10 test per day) and flowcytometry (30 ~ 50 test per day, including incubation times for fluorescent cell staining). Overall platform performance is important for clinical applications. The mean and the standard deviation of overall platform performance was 83.5 ± 2.44 %. The repeatable performance allows correcting for the length dependent counting bias (in this case divide by the mean value, 0.835). The corrected CD4+ cell count estimate should be clinically acceptable given that the chip capture efficiency is repeatable within 2.44 %. This standard deviation value currently satisfies the clinical need (± 10 % overall count error) with the bias correction approach.
III. CONCLUSIONS
We demonstrated a novel method to build a point-of-care device that can be merged with lens-less imaging for rapid automatic cell counting, i.e. CD4 counts. The lens-less CCD imaging platform merged with label-free cell capturing is potentially useful for resource-limited settings, since it eliminates the need for fluorescent imaging; it reduces the time for cell capture, imaging, and counting to a few minutes from hours. The merger of the microchip with the CCD was successful to capture, image and automatically count the CD4+ T-Iymphocytes. This integrated system poses a future direction for point-of-care testing especially focusing on global health applications at resource limited settings. 
